On Friday, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) opened lower -6.67% from the last session, before settling in for the closing price of $8.70. Price fluctuations for DAWN have ranged from $7.88 to $18.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -34.65% at the time writing. With a float of $74.28 million, this company’s outstanding shares have now reached $101.12 million.
Let’s look at the performance matrix of the company that is accounted for 181 employees. In terms of profitability, gross margin is 95.89%, operating margin of -165.65%, and the pretax margin is -67.36%.
Day One Biopharmaceuticals Inc (DAWN) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Day One Biopharmaceuticals Inc is 26.71%, while institutional ownership is 83.58%. The most recent insider transaction that took place on Feb 18 ’25, was worth 52,278. In this transaction COO, CFO AND SECRETARY of this company sold 4,370 shares at a rate of $11.96, taking the stock ownership to the 252,638 shares. Before that another transaction happened on Feb 18 ’25, when Company’s GENERAL COUNSEL sold 4,646 for $11.96, making the entire transaction worth $55,580. This insider now owns 39,602 shares in total.
Day One Biopharmaceuticals Inc (DAWN) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.39 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -34.65% per share during the next fiscal year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Check out the current performance indicators for Day One Biopharmaceuticals Inc (DAWN). In the past quarter, the stock posted a quick ratio of 7.61. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.04, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -0.53 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) saw its 5-day average volume 1.34 million, a positive change from its year-to-date volume of 1.22 million. As of the previous 9 days, the stock’s Stochastic %D was 35.50%. Additionally, its Average True Range was 0.65.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 2.70%, which indicates a significant decrease from 5.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 112.31% in the past 14 days, which was higher than the 56.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.37, while its 200-day Moving Average is $13.31. Nevertheless, the first resistance level for the watch stands at $8.64 in the near term. At $9.16, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.43. If the price goes on to break the first support level at $7.85, it is likely to go to the next support level at $7.58. The third support level lies at $7.06 if the price breaches the second support level.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
There are currently 101,355K shares outstanding in the company with a market cap of 823.00 million. Presently, the company’s annual sales total 131,160 K according to its annual income of -95,500 K. Last quarter, the company’s sales amounted to 29,210 K and its income totaled -65,710 K.
